Cargando…
High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs
BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ES...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290529/ https://www.ncbi.nlm.nih.gov/pubmed/32566630 http://dx.doi.org/10.21037/atm.2020.02.158 |
_version_ | 1783545698051948544 |
---|---|
author | Romo-Ibáñez, Álvaro Calatrava-Hernández, Elisabeth Gutiérrez-Soto, Blanca Pérez-Ruiz, Mercedes Navarro-Marí, José María Gutiérrez-Fernández, José |
author_facet | Romo-Ibáñez, Álvaro Calatrava-Hernández, Elisabeth Gutiérrez-Soto, Blanca Pérez-Ruiz, Mercedes Navarro-Marí, José María Gutiérrez-Fernández, José |
author_sort | Romo-Ibáñez, Álvaro |
collection | PubMed |
description | BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria. METHODS: Vancomycin, cefoxitin, imipenem, and cefepime disks were used to measure growth on CHROMID ESBL medium of β-lactam-resistant Gram-negative (83 with ESBL, 57 with carbapenemases, 35 with AmpC and 3 Stenotrophomonas maltophilia) and Gram-positive [37 vancomycin-susceptible (vancoS) microorganisms and 21 vancomycin-resistant (vancoR) Enterococcus faecium] clinical isolates (retrospective study) and colonization by the aforementioned bacteria (prospective study), using 649 rectal swabs, 314 pharyngeal swabs, and 44 swabs from other localizations. RESULTS: Retrospective study: species grown on the medium exhibited different colors. Growth on the medium was observed for: all ESBL enterobacteria, which were susceptible to imipenem and cefoxitin; 95% of isolates with carbapenemases, mostly resistant to imipenem; 80% of those with AmpC; 86% of vancoR E. faecium isolates; and 42% of vancoS E. faecalis isolates, with large growth inhibition halos around the vancomycin disk. Prospective study: vancoR E. faecium, ESBL Klebsiella, Pseudomonas with carbapenemases, A. baumannii (mostly from rectal swabs), S. maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia (mostly from pharyngeal swabs) were isolated from the 246 positive samples. CONCLUSIONS: CHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemase-producing microorganisms grew around the imipenem disk, and vancoR E. faecium was isolated on the medium. Results of the prospective study demonstrate the potential clinical relevance of this medium. S. maltophilia was more frequently detected with pharyngeal swabs and ESBL Klebsiella, A. baumannii, and Pseudomonas with rectal swabs. |
format | Online Article Text |
id | pubmed-7290529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-72905292020-06-19 High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs Romo-Ibáñez, Álvaro Calatrava-Hernández, Elisabeth Gutiérrez-Soto, Blanca Pérez-Ruiz, Mercedes Navarro-Marí, José María Gutiérrez-Fernández, José Ann Transl Med Original Article on Advances in Laboratory Tests for Infectious Diseases BACKGROUND: Antibiotic resistance is a serious public health challenge exacerbated by the widespread use of β-lactam and glycopeptide antibiotics. The identification of resistances is crucial, and CHROMID ESBL medium has been developed to detect enterobacteria with extended-spectrum β-lactamases (ESBL). The objective of this study was to evaluate the potential of this medium to detect other types of resistant bacteria. METHODS: Vancomycin, cefoxitin, imipenem, and cefepime disks were used to measure growth on CHROMID ESBL medium of β-lactam-resistant Gram-negative (83 with ESBL, 57 with carbapenemases, 35 with AmpC and 3 Stenotrophomonas maltophilia) and Gram-positive [37 vancomycin-susceptible (vancoS) microorganisms and 21 vancomycin-resistant (vancoR) Enterococcus faecium] clinical isolates (retrospective study) and colonization by the aforementioned bacteria (prospective study), using 649 rectal swabs, 314 pharyngeal swabs, and 44 swabs from other localizations. RESULTS: Retrospective study: species grown on the medium exhibited different colors. Growth on the medium was observed for: all ESBL enterobacteria, which were susceptible to imipenem and cefoxitin; 95% of isolates with carbapenemases, mostly resistant to imipenem; 80% of those with AmpC; 86% of vancoR E. faecium isolates; and 42% of vancoS E. faecalis isolates, with large growth inhibition halos around the vancomycin disk. Prospective study: vancoR E. faecium, ESBL Klebsiella, Pseudomonas with carbapenemases, A. baumannii (mostly from rectal swabs), S. maltophilia, Achromobacter xylosoxidans, and Burkholderia cenocepacia (mostly from pharyngeal swabs) were isolated from the 246 positive samples. CONCLUSIONS: CHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemase-producing microorganisms grew around the imipenem disk, and vancoR E. faecium was isolated on the medium. Results of the prospective study demonstrate the potential clinical relevance of this medium. S. maltophilia was more frequently detected with pharyngeal swabs and ESBL Klebsiella, A. baumannii, and Pseudomonas with rectal swabs. AME Publishing Company 2020-05 /pmc/articles/PMC7290529/ /pubmed/32566630 http://dx.doi.org/10.21037/atm.2020.02.158 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article on Advances in Laboratory Tests for Infectious Diseases Romo-Ibáñez, Álvaro Calatrava-Hernández, Elisabeth Gutiérrez-Soto, Blanca Pérez-Ruiz, Mercedes Navarro-Marí, José María Gutiérrez-Fernández, José High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs |
title | High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs |
title_full | High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs |
title_fullStr | High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs |
title_full_unstemmed | High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs |
title_short | High clinical impact of rapid susceptibility testing on CHROMID ESBL(®) medium directly from swabs |
title_sort | high clinical impact of rapid susceptibility testing on chromid esbl(®) medium directly from swabs |
topic | Original Article on Advances in Laboratory Tests for Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290529/ https://www.ncbi.nlm.nih.gov/pubmed/32566630 http://dx.doi.org/10.21037/atm.2020.02.158 |
work_keys_str_mv | AT romoibanezalvaro highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs AT calatravahernandezelisabeth highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs AT gutierrezsotoblanca highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs AT perezruizmercedes highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs AT navarromarijosemaria highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs AT gutierrezfernandezjose highclinicalimpactofrapidsusceptibilitytestingonchromidesblmediumdirectlyfromswabs |